Correcting the Hype One Company at a Time | GenomeWeb

In this Forbes Q&A, Matthew Herper interviews James Thomson, who's recently started his own company, Cellular Dynamics International, which is focused on testing experimental drugs for heart side effects. Rather than cave into the hype surrounding regenerative medicine, he sees much bigger opportunities for stem cells as a research tool and in drug discovery.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.